GR3004912T3 - - Google Patents

Info

Publication number
GR3004912T3
GR3004912T3 GR920401262T GR920401262T GR3004912T3 GR 3004912 T3 GR3004912 T3 GR 3004912T3 GR 920401262 T GR920401262 T GR 920401262T GR 920401262 T GR920401262 T GR 920401262T GR 3004912 T3 GR3004912 T3 GR 3004912T3
Authority
GR
Greece
Application number
GR920401262T
Other languages
Greek (el)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK503386A external-priority patent/DK503386D0/da
Priority claimed from DK356987A external-priority patent/DK356987D0/da
Application filed filed Critical
Publication of GR3004912T3 publication Critical patent/GR3004912T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
GR920401262T 1986-10-20 1992-06-11 GR3004912T3 (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK503386A DK503386D0 (da) 1986-10-20 1986-10-20 Peptidpraeparater
DK356987A DK356987D0 (en:Method) 1987-07-10 1987-07-10

Publications (1)

Publication Number Publication Date
GR3004912T3 true GR3004912T3 (en:Method) 1993-04-28

Family

ID=26067111

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920401262T GR3004912T3 (en:Method) 1986-10-20 1992-06-11

Country Status (18)

Country Link
US (1) US5070186A (en:Method)
EP (1) EP0265213B1 (en:Method)
KR (1) KR880004819A (en:Method)
CN (1) CN87107049A (en:Method)
AU (1) AU616381B2 (en:Method)
CA (1) CA1316819C (en:Method)
DE (1) DE3778287D1 (en:Method)
ES (1) ES2033871T3 (en:Method)
FI (1) FI86254C (en:Method)
GR (1) GR3004912T3 (en:Method)
HU (1) HU201475B (en:Method)
IE (1) IE60264B1 (en:Method)
IL (1) IL84203A (en:Method)
NO (1) NO170754C (en:Method)
NZ (1) NZ222214A (en:Method)
PH (1) PH23446A (en:Method)
PT (1) PT85949B (en:Method)
YU (1) YU46665B (en:Method)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
JP2002500196A (ja) * 1998-01-09 2002-01-08 ノヴォ ノルディスク アクティーゼルスカブ 安定化させたインスリン組成物
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ATE333260T1 (de) * 2001-08-27 2006-08-15 Novo Nordisk As Eine patrone und ein medizinisches anlieferungssystem das solch eine patrone unterbringt
MXPA05007182A (es) * 2002-12-31 2006-04-07 Altus Pharmaceuticals Inc Complejos de cristales de proteina y polimeros ionicos.
MXPA05007181A (es) * 2002-12-31 2006-04-07 Altus Pharmaceuticals Inc Cristales de la hormona de crecimiento humano y metodos para prepararlos.
JP2009521486A (ja) * 2005-12-23 2009-06-04 アルタス ファーマシューティカルズ インコーポレイテッド ポリカチオン錯化タンパク質結晶を含む組成物およびこれを使用した治療法
WO2008015099A2 (en) 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
PT2074141T (pt) 2006-09-22 2016-11-10 Novo Nordisk As Análogos de insulina resistentes a proteases
JP2010525033A (ja) * 2007-04-30 2010-07-22 ノボ・ノルデイスク・エー/エス 高濃縮のインスリン溶液及び組成物
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー/エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
BRPI0910348B1 (pt) 2008-03-18 2021-06-29 Novo Nordisk A/S Insulina estabilizada em protease acilada, composição farmacêutica compreendendo a mesma e seus usos
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
PL2498802T3 (pl) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
US8637458B2 (en) * 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
KR101823320B1 (ko) 2010-08-30 2018-01-31 사노피-아벤티스 도이칠란트 게엠베하 제2형 진성 당뇨병 치료용 약제를 제조하기 위한 ave0010의 용도
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
DK2750699T3 (en) 2011-08-29 2015-10-26 Sanofi Aventis Deutschland A pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AU2013247047A1 (en) 2012-04-11 2014-10-23 Novo Nordisk A/S Insulin formulations
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
MX369511B (es) 2013-04-03 2019-11-11 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
CN105636979B (zh) 2013-10-07 2020-01-10 诺和诺德股份有限公司 胰岛素类似物的新衍生物
TN2017000235A1 (en) 2014-12-12 2018-10-19 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
RU2758367C2 (ru) 2016-12-16 2021-10-28 Ново Нордиск А/С Фармацевтические композиции, содержащие инсулин

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2076082A (en) * 1935-04-08 1937-04-06 Nordisk Insulinlab Therapeutic product and process
US2179384A (en) * 1937-04-05 1939-11-07 Univ Alberta Therapeutic composition and process of making it
US2190134A (en) * 1939-06-09 1940-02-13 Norton Co Grinding machine
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2474729A (en) * 1945-01-03 1949-06-28 Rhone Poulenc Sa Insulin preparations
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
DK98342C (da) * 1959-06-16 1964-03-31 Henry Marinus Dr Christensen Fremgangsmåde til fremstilling af et insulinpræparat til peroral applikation.
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1426061A (en) * 1972-12-28 1976-02-25 Ici Ltd Polypeptides
US3856771A (en) * 1973-07-16 1974-12-24 Lilly Co Eli Process for manufacturing alkali metal or ammonium insulin
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
AU550068B2 (en) * 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production

Also Published As

Publication number Publication date
FI874596L (fi) 1988-04-21
FI86254B (fi) 1992-04-30
PT85949A (en) 1987-11-01
AU7990787A (en) 1988-04-21
KR880004819A (ko) 1988-06-27
YU191887A (en) 1989-04-30
EP0265213A3 (en) 1988-11-09
NO874347D0 (no) 1987-10-19
EP0265213B1 (en) 1992-04-15
NZ222214A (en) 1989-11-28
IE60264B1 (en) 1994-06-29
NO170754C (no) 1992-12-02
HUT46232A (en) 1988-10-28
CN87107049A (zh) 1988-07-06
PH23446A (en) 1989-08-07
YU46665B (sh) 1994-01-20
HU201475B (en) 1990-11-28
DE3778287D1 (de) 1992-05-21
PT85949B (pt) 1990-07-31
FI874596A0 (fi) 1987-10-19
IL84203A (en) 1993-04-04
AU616381B2 (en) 1991-10-31
US5070186A (en) 1991-12-03
EP0265213A2 (en) 1988-04-27
CA1316819C (en) 1993-04-27
ES2033871T3 (es) 1993-04-01
NO874347L (no) 1988-04-21
NO170754B (no) 1992-08-24
FI86254C (fi) 1992-08-10
IE872799L (en) 1988-04-20

Similar Documents

Publication Publication Date Title
AU7131891A (en:Method)
GR3004912T3 (en:Method)
AU7354491A (en:Method)
AU6562586A (en:Method)
AU7131791A (en:Method)
AU5480786A (en:Method)
AU5703286A (en:Method)
AU5257190A (en:Method)
AU5329886A (en:Method)
AU5344086A (en:Method)
AU5348186A (en:Method)
AU5442686A (en:Method)
AU5130385A (en:Method)
AU5558386A (en:Method)
AU5597686A (en:Method)
AU5614386A (en:Method)
AU5614486A (en:Method)
AU5644686A (en:Method)
AU6011386A (en:Method)
AU5684886A (en:Method)
BE905135A (en:Method)
AU5724586A (en:Method)
AU5745586A (en:Method)
AU5753186A (en:Method)
AU5767086A (en:Method)